|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q37838188
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241121000158.0 |
|
008
|
|
|
241121nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q37838188
|
|
024
|
|
|
‡a
0000-0003-2172-0931
‡2
orcid
|
|
035
|
|
|
‡a
(OCoLC)Q37838188
|
|
100
|
0 |
|
‡a
William L Baker
‡9
ast
‡9
sl
‡9
es
|
|
375
|
|
|
‡a
1
‡2
iso5218
|
|
400
|
0 |
|
‡a
উইলিয়াম এল বেকার
‡c
গবেষক
‡9
bn
|
|
400
|
0 |
|
‡a
William L. Baker
‡c
researcher (ORCID 0000-0003-2172-0931)
‡9
en
|
|
400
|
0 |
|
‡a
William L. Baker
‡c
ricercatore
‡9
it
|
|
400
|
0 |
|
‡a
William L Baker
‡c
wetenschapper
‡9
nl
|
|
670
|
|
|
‡a
Author's A meta-analysis evaluating the impact of chitosan on serum lipids in hypercholesterolemic patients
|
|
670
|
|
|
‡a
Author's A multidisciplinary team-based process improves outpatient anticoagulation quality with continuous-flow left-ventricular assist devices
|
|
670
|
|
|
‡a
Author's Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis
|
|
670
|
|
|
‡a
Author's Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults
|
|
670
|
|
|
‡a
Author's Agency for Healthcare Research and Quality Evidence-based Practice Center methods provide guidance on prioritization and selection of harms in systematic reviews
|
|
670
|
|
|
‡a
Author's Anticoagulation for the Treatment of Cancer-Associated Thrombosis: A Systematic Review and Network Meta-Analysis of Randomized Trials
|
|
670
|
|
|
‡a
Author's Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials
|
|
670
|
|
|
‡a
Author's Antiplatelet agents for the prevention of arteriovenous fistula and graft thrombosis: a meta analysis.
|
|
670
|
|
|
‡a
Author's Are the risk factors listed in warfarin prescribing information associated with anticoagulation-related bleeding? A systematic literature review.
|
|
670
|
|
|
‡a
Author's Assessing the usefulness of health-related quality-of-life trials: a clinician's perspective using two COPD examples
|
|
670
|
|
|
‡a
Author's Association between CHADS₂risk factors and anticoagulation-related bleeding: a systematic literature review.
|
|
670
|
|
|
‡a
Author's Association between HBsAg positivity and pancreatic cancer: a meta-analysis
|
|
670
|
|
|
‡a
Author's Association between perioperative NSAID use and post-cardiothoracic surgery atrial fibrillation, blood transfusions, and cardiovascular outcomes: a nested cohort study from the AF Suppression Trials (AFIST) I, II and III
|
|
670
|
|
|
‡a
Author's Association Between Time-in-Therapeutic Tacrolimus Range and Early Rejection After Heart Transplant
|
|
670
|
|
|
‡a
Author's Association between weekend admission and mortality for upper gastrointestinal hemorrhage: an observational study and meta-analysis.
|
|
670
|
|
|
‡a
Author's Association of Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists With Asthma Control in Patients With Uncontrolled, Persistent Asthma: A Systematic Review and Meta-analysis
|
|
670
|
|
|
‡a
Author's Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis
|
|
670
|
|
|
‡a
Author's Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension
|
|
670
|
|
|
‡a
Author's Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis
|
|
670
|
|
|
‡a
Author's Baseline and postoperative levels of C-reactive protein and interleukins as inflammatory predictors of atrial fibrillation following cardiac surgery: a systematic review and meta-analysis
|
|
670
|
|
|
‡a
Author's BDNF Val66Met polymorphism and lithium response: a meta-analysis
|
|
670
|
|
|
‡a
Author's Benefit-risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients
|
|
670
|
|
|
‡a
Author's Benefits and risks associated with beta-blocker prophylaxis in noncardiac surgery.
|
|
670
|
|
|
‡a
Author's Beyond the guidelines: new and novel agents for the prevention of atrial fibrillation after cardiothoracic surgery
|
|
670
|
|
|
‡a
Author's Can apixaban prevent venous thromboembolism better than rivaroxaban?
|
|
670
|
|
|
‡a
Author's Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes
|
|
670
|
|
|
‡a
Author's Cardiac MRI-confirmed mesalamine-induced myocarditis
|
|
670
|
|
|
‡a
Author's Cardiovascular Effects of Incretin-Based Therapies
|
|
670
|
|
|
‡a
Author's Cardiovascular effects of pharmacologic therapies for smoking cessation
|
|
670
|
|
|
‡a
Author's Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis
|
|
670
|
|
|
‡a
Author's Combination therapy for the management of hypertension: A review of the evidence.
|
|
670
|
|
|
‡a
Author's Common flaws exist in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillation
|
|
670
|
|
|
‡a
Author's Comparative Effectiveness of Analgesics to Reduce Acute Pain in the Prehospital Setting
|
|
670
|
|
|
‡a
Author's Cryoballoon Ablation for the Treatment of Atrial Fibrillation: A Meta-analysis
|
|
670
|
|
|
‡a
Author's Current Status of Patient Radiation Exposure of Cardiac Positron Emission Tomography and Single-Photon Emission Computed Tomographic Myocardial Perfusion Imaging
|
|
670
|
|
|
‡a
Author's Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation
|
|
670
|
|
|
‡a
Author's Deaths and cardiovascular events in men receiving testosterone
|
|
670
|
|
|
‡a
Author's Development of critical thinking in health professions education: A meta-analysis of longitudinal studies
|
|
670
|
|
|
‡a
Author's Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis
|
|
670
|
|
|
‡a
Author's Effect of ascorbic acid on inflammatory markers after cardiothoracic surgery
|
|
670
|
|
|
‡a
Author's Effect of cinnamon on glucose control and lipid parameters
|
|
670
|
|
|
‡a
Author's Effect of dehydroepiandrosterone on muscle strength and physical function in older adults: a systematic review.
|
|
670
|
|
|
‡a
Author's Effect of Intensive Blood Pressure Control in Patients with Type 2 Diabetes Mellitus Over 9 Years of Follow-Up: A Subgroup Analysis of High-Risk ACCORDION Trial Participants.
|
|
670
|
|
|
‡a
Author's Effect of magnesium L-lactate on blood pressure in patients with an implantable cardioverter defibrillator
|
|
670
|
|
|
‡a
Author's Effect of nonergot dopamine agonists on symptoms of restless legs syndrome.
|
|
670
|
|
|
‡a
Author's Effect of perioperative corticosteroid use on the incidence of postcardiothoracic surgery atrial fibrillation and length of stay.
|
|
670
|
|
|
‡a
Author's Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis
|
|
670
|
|
|
‡a
Author's Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis
|
|
670
|
|
|
‡a
Author's Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis
|
|
670
|
|
|
‡a
Author's Efficacy of azilsartan medoxomil with chlorthalidone in hypertension
|
|
670
|
|
|
‡a
Author's Electrocardiographic effects of hawthorn (Crataegus oxyacantha) in healthy volunteers: A randomized controlled trial
|
|
670
|
|
|
‡a
Author's Erratum. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. Diabetes Care 2017;40:1733-1738
|
|
670
|
|
|
‡a
Author's Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus
|
|
670
|
|
|
‡a
Author's Evaluating the impact of study-level factors on warfarin control in U.S.-based primary studies: a meta-analysis.
|
|
670
|
|
|
‡a
Author's Evaluation of Posttransplantation Diabetes Mellitus After Liver Transplantation: Assessment of Insulin Administration as a Risk Factor.
|
|
670
|
|
|
‡a
Author's Four-year incidence of major adverse cardiovascular events in patients with atherosclerosis and atrial fibrillation
|
|
670
|
|
|
‡a
Author's Haematological indices as predictors of atrial fibrillation following isolated coronary artery bypass grafting, valvular surgery, or combined procedures: a systematic review with meta-analysis
|
|
670
|
|
|
‡a
Author's Hemodynamic and electrocardiographic effects of açaí berry in healthy volunteers: a randomized controlled trial
|
|
670
|
|
|
‡a
Author's Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE
|
|
670
|
|
|
‡a
Author's Improved glucose control associated with i.v. chromium administration in two patients receiving enteral nutrition
|
|
670
|
|
|
‡a
Author's Improving peer review: What authors can do.
|
|
670
|
|
|
‡a
Author's Improving peer review: What journals can do.
|
|
670
|
|
|
‡a
Author's Improving peer review: What reviewers can do.
|
|
670
|
|
|
‡a
Author's Increased clinical failures when treating acute otitis media with macrolides: a meta-analysis
|
|
670
|
|
|
‡a
Author's Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation
|
|
670
|
|
|
‡a
Author's Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP.
|
|
670
|
|
|
‡a
Author's Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma
|
|
670
|
|
|
‡a
Author's Intravenous Acetaminophen for Postoperative Pain Management in Patients Undergoing Living Laparoscopic Living-Donor Nephrectomy
|
|
670
|
|
|
‡a
Author's Key articles and guidelines in the acute management and secondary prevention of ischemic stroke
|
|
670
|
|
|
‡a
Author's Key articles and guidelines in the management of patients undergoing cardiac surgery
|
|
670
|
|
|
‡a
Author's Key articles and guidelines in the primary prevention of ischemic stroke.
|
|
670
|
|
|
‡a
Author's Letter by Baker et al regarding article, "benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response meta-analysis"
|
|
670
|
|
|
‡a
Author's Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity
|
|
670
|
|
|
‡a
Author's Mammalian Target of Rapamycin Inhibitors and Survival in Heart Transplant Recipients: Miracle or Mirage?
|
|
670
|
|
|
‡a
Author's Mechanical endovascular therapy for acute ischemic stroke: An indirect treatment comparison between Solitaire and Penumbra thrombectomy devices.
|
|
670
|
|
|
‡a
Author's Medication adherence and non-vitamin K antagonist oral anticoagulants: what do we really know?
|
|
670
|
|
|
‡a
Author's Medications for Asthma
|
|
670
|
|
|
‡a
Author's Meta-analysis of optimal risk stratification in patients >65 years of age
|
|
670
|
|
|
‡a
Author's Meta-Analysis of Time in Therapeutic Range in Continuous-Flow Left Ventricular Assist Device Patients Receiving Warfarin.
|
|
670
|
|
|
‡a
Author's Methods used to conduct and report Bayesian mixed treatment comparisons published in the medical literature: a systematic review
|
|
670
|
|
|
‡a
Author's Myth Busters: Dietary Supplements and COVID-19
|
|
670
|
|
|
‡a
Author's New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics?
|
|
670
|
|
|
‡a
Author's Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models.
|
|
670
|
|
|
‡a
Author's Oral antidiabetic drugs and regression from prediabetes to normoglycemia: a meta-analysis
|
|
670
|
|
|
‡a
Author's Outcomes associated with mammalian target of rapamycin
|
|
670
|
|
|
‡a
Author's Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: A meta-analysis.
|
|
670
|
|
|
‡a
Author's Pharmacogenetics and oral antithrombotic drugs
|
|
670
|
|
|
‡a
Author's Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors
|
|
670
|
|
|
‡a
Author's Pitavastatin: a new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia.
|
|
670
|
|
|
‡a
Author's Post-cardiothoracic surgery atrial fibrillation: a review of preventive strategies.
|
|
670
|
|
|
‡a
Author's Postoperative atrial fibrillation - what do we really know?
|
|
670
|
|
|
‡a
Author's Prasugrel: a critical comparison with clopidogrel.
|
|
670
|
|
|
‡a
Author's Pre-Cardiac Transplant Amiodarone Use Increases Postoperative Mortality: A Meta-analysis
|
|
670
|
|
|
‡a
Author's Pre-cardiac transplant amiodarone use is not associated with postoperative mortality: An updated meta-analysis.
|
|
670
|
|
|
‡a
Author's Prioritization and Selection of Harms for Inclusion in Systematic Reviews
|
|
670
|
|
|
‡a
Author's Resolution of a phytobezoar with Aldoph's Meat Tenderizer
|
|
670
|
|
|
‡a
Author's Response to Comment on Buckley et al. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. Diabetes Care 2017;40:1733-1738
|
|
670
|
|
|
‡a
Author's Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes
|
|
670
|
|
|
‡a
Author's Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis
|
|
670
|
|
|
‡a
Author's Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension
|
|
670
|
|
|
‡a
Author's Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation
|
|
670
|
|
|
‡a
Author's Systematic Review and Meta-Analysis of Real-World Studies Evaluating Rivaroxaban for Cancer-Associated Venous Thrombosis.
|
|
670
|
|
|
‡a
Author's Systematic Review of Phosphodiesterase-5 Inhibitor Use in Right Ventricular Failure Following Left Ventricular Assist Device Implantation
|
|
670
|
|
|
‡a
Author's The association among blood transfusions, white blood cell count, and the frequency of post-cardiothoracic surgery atrial fibrillation: a nested cohort study from the Atrial Fibrillation Suppression Trials I, II, and III.
|
|
670
|
|
|
‡a
Author's The changing face of anticoagulation management: an improving countenance
|
|
670
|
|
|
‡a
Author's The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker
|
|
670
|
|
|
‡a
Author's The effect of adding plant sterols or stanols to statin therapy in hypercholesterolemic patients: systematic review and meta-analysis
|
|
670
|
|
|
‡a
Author's The effects of barley-derived soluble fiber on serum lipids
|
|
670
|
|
|
‡a
Author's The impact of carvedilol on the defibrillation threshold
|
|
670
|
|
|
‡a
Author's The role of the clinical pharmacist in the care of patients with cardiovascular disease
|
|
670
|
|
|
‡a
Author's Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose
|
|
670
|
|
|
‡a
Author's Use of N-acetylcysteine to reduce post-cardiothoracic surgery complications: a meta-analysis
|
|
670
|
|
|
‡a
Author's Use of preoperative CHA2 DS2 -VASc score to predict the risk of atrial fibrillation after cardiothoracic surgery: a nested case-control study from the Atrial Fibrillation Suppression Trials (AFIST) I, II, and III
|
|
670
|
|
|
‡a
Author's Vasopressin therapy in cardiac surgery
|
|
670
|
|
|
‡a
Author's Walking speed and health-related quality of life in multiple sclerosis
|
|
670
|
|
|
‡a
wikidata authority control
‡u
https://viaf.org/viaf/140152138557110980427
|
|
909
|
|
|
‡a
(orcid) 0000000321720931
‡9
1
|
|
919
|
|
|
‡a
baselineandpostoperativelevelsof100reactiveproteinandinterleukinsasinflammatorypredictorsofatrialfibrillationfollowingcardiacsurgeryasystematicreviewandmetaanalysis
‡A
Baseline and postoperative levels of C-reactive protein and interleukins as inflammatory predictors of atrial fibrillation following cardiac surgery: a systematic review and meta-analysis
‡9
1
|
|
919
|
|
|
‡a
azilsartanmedoxomilanewangiotensin2receptorantagonistfortreatmentofhypertension
‡A
Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension
‡9
1
|
|
919
|
|
|
‡a
metaanalysisevaluatingtheimpactofchitosanonserumlipidsinhypercholesterolemicpatients
‡A
A meta-analysis evaluating the impact of chitosan on serum lipids in hypercholesterolemic patients
‡9
1
|
|
919
|
|
|
‡a
azithromycinforthesecondarypreventionofcoronaryarterydiseaseametaanalysis
‡A
Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis
‡9
1
|
|
919
|
|
|
‡a
multidisciplinaryteambasedprocessimprovesoutpatientanticoagulationqualitywithcontinuousflowleftventricularassistdevices
‡A
A multidisciplinary team-based process improves outpatient anticoagulation quality with continuous-flow left-ventricular assist devices
‡9
1
|
|
919
|
|
|
‡a
addingadopamineagonisttopreexistinglevodopatherapyvslevodopatherapyaloneinadvancedparkinsonsdiseaseametaanalysis
‡A
Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis
‡9
1
|
|
919
|
|
|
‡a
adverseeffectsofpharmacologictreatmentsofmajordepressioninolderadults
‡A
Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults
‡9
1
|
|
919
|
|
|
‡a
agencyforhealthcareresearchandqualityevidencebasedpracticecentermethodsprovideguidanceonprioritizationandselectionofharmsinsystematicreviews
‡A
Agency for Healthcare Research and Quality Evidence-based Practice Center methods provide guidance on prioritization and selection of harms in systematic reviews
‡9
1
|
|
919
|
|
|
‡a
anticoagulationforthetreatmentofcancerassociatedthrombosisasystematicreviewandnetworkmetaanalysisofrandomizedtrials
‡A
Anticoagulation for the Treatment of Cancer-Associated Thrombosis: A Systematic Review and Network Meta-Analysis of Randomized Trials
‡9
1
|
|
919
|
|
|
‡a
antihypertensivemedicationandtheirimpactoncancerincidenceamixedtreatmentcomparisonmetaanalysisofrandomizedcontrolledtrials
‡A
Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials
‡9
1
|
|
919
|
|
|
‡a
antiplateletagentsforthepreventionofarteriovenousfistulaandgraftthrombosisametaanalysis
‡A
Antiplatelet agents for the prevention of arteriovenous fistula and graft thrombosis: a meta analysis.
‡9
1
|
|
919
|
|
|
‡a
aretheriskfactorslistedinwarfarinprescribinginformationassociatedwithanticoagulationrelatedbleedingasystematicliteraturereview
‡A
Are the risk factors listed in warfarin prescribing information associated with anticoagulation-related bleeding? A systematic literature review.
‡9
1
|
|
919
|
|
|
‡a
assessingtheusefulnessofhealthrelatedqualityoflifetrialsacliniciansperspectiveusing2copdexamples
‡A
Assessing the usefulness of health-related quality-of-life trials: a clinician's perspective using two COPD examples
‡9
1
|
|
919
|
|
|
‡a
walkingspeedandhealthrelatedqualityoflifeinmultiplesclerosis
‡A
Walking speed and health-related quality of life in multiple sclerosis
‡9
1
|
|
919
|
|
|
‡a
vasopressintherapyincardiacsurgery
‡A
Vasopressin therapy in cardiac surgery
‡9
1
|
|
919
|
|
|
‡a
useofpreoperativecha2ds2vascscoretopredicttheriskofatrialfibrillationaftercardiothoracicsurgeryanestedcasecontrolstudyfromtheatrialfibrillationsuppressiontrialsafist12and3
‡A
Use of preoperative CHA2 DS2 -VASc score to predict the risk of atrial fibrillation after cardiothoracic surgery: a nested case-control study from the Atrial Fibrillation Suppression Trials (AFIST) I, II, and III
‡9
1
|
|
919
|
|
|
‡a
useofnacetylcysteinetoreducepostcardiothoracicsurgerycomplicationsametaanalysis
‡A
Use of N-acetylcysteine to reduce post-cardiothoracic surgery complications: a meta-analysis
‡9
1
|
|
919
|
|
|
‡a
toxicityofchloroquineandhydroxychloroquinefollowingtherapeuticuseoroverdose
‡A
Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose
‡9
1
|
|
919
|
|
|
‡a
roleoftheclinicalpharmacistinthecareofpatientswithcardiovasculardisease
‡A
The role of the clinical pharmacist in the care of patients with cardiovascular disease
‡9
1
|
|
919
|
|
|
‡a
impactofcarvedilolonthedefibrillationthreshold
‡A
The impact of carvedilol on the defibrillation threshold
‡9
1
|
|
919
|
|
|
‡a
effectsofbarleyderivedsolublefiberonserumlipids
‡A
The effects of barley-derived soluble fiber on serum lipids
‡9
1
|
|
919
|
|
|
‡a
effectofaddingplantsterolsorstanolstostatintherapyinhypercholesterolemicpatientssystematicreviewandmetaanalysis
‡A
The effect of adding plant sterols or stanols to statin therapy in hypercholesterolemic patients: systematic review and meta-analysis
‡9
1
|
|
919
|
|
|
‡a
developmentofnewonsettype2diabetesassociatedwithchoosingacalciumchannelblockercomparedtoadiureticorbetablocker
‡A
The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker
‡9
1
|
|
919
|
|
|
‡a
changingfaceofanticoagulationmanagementanimprovingcountenance
‡A
The changing face of anticoagulation management: an improving countenance
‡9
1
|
|
919
|
|
|
‡a
associationamongbloodtransfusionswhitebloodcellcountandthefrequencyofpostcardiothoracicsurgeryatrialfibrillationanestedcohortstudyfromtheatrialfibrillationsuppressiontrials12and3
‡A
The association among blood transfusions, white blood cell count, and the frequency of post-cardiothoracic surgery atrial fibrillation: a nested cohort study from the Atrial Fibrillation Suppression Trials I, II, and III.
‡9
1
|
|
919
|
|
|
‡a
systematicreviewofphosphodiesterase5inhibitoruseinrightventricularfailurefollowingleftventricularassistdeviceimplantation
‡A
Systematic Review of Phosphodiesterase-5 Inhibitor Use in Right Ventricular Failure Following Left Ventricular Assist Device Implantation
‡9
1
|
|
919
|
|
|
‡a
systematicreviewandmetaanalysisofrealworldstudiesevaluatingrivaroxabanforcancerassociatedvenousthrombosis
‡A
Systematic Review and Meta-Analysis of Real-World Studies Evaluating Rivaroxaban for Cancer-Associated Venous Thrombosis.
‡9
1
|
|
919
|
|
|
‡a
systematicreviewandadjustedindirectcomparisonmetaanalysisoforalanticoagulantsinatrialfibrillation
‡A
Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation
‡9
1
|
|
919
|
|
|
‡a
selexipaganoralprostacyclinreceptoragonistforpulmonaryarterialhypertension
‡A
Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension
‡9
1
|
|
919
|
|
|
‡a
safetyofmineralocorticoidreceptorantagonistsinpatientsreceivinghemodialysis
‡A
Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis
‡9
1
|
|
919
|
|
|
‡a
roleofprasugrelanovelp2y12receptorantagonistinthemanagementofacutecoronarysyndromes
‡A
Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes
‡9
1
|
|
919
|
|
|
‡a
responsetocommentonbuckleyetalintensiveversusstandardbloodpressurecontrolinsprinteligibleparticipantsofaccordbpdiabetescare2017401733
‡A
Response to Comment on Buckley et al. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. Diabetes Care 2017;40:1733-1738
‡9
1
|
|
919
|
|
|
‡a
resolutionofaphytobezoarwithaldophsmeattenderizer
‡A
Resolution of a phytobezoar with Aldoph's Meat Tenderizer
‡9
1
|
|
919
|
|
|
‡a
prioritizationandselectionofharmsforinclusioninsystematicreviews
‡A
Prioritization and Selection of Harms for Inclusion in Systematic Reviews
‡9
1
|
|
919
|
|
|
‡a
precardiactransplantamiodaroneuseisnotassociatedwithpostoperativemortalityanupdatedmetaanalysis
‡A
Pre-cardiac transplant amiodarone use is not associated with postoperative mortality: An updated meta-analysis.
‡9
1
|
|
919
|
|
|
‡a
precardiactransplantamiodaroneuseincreasespostoperativemortalityametaanalysis
‡A
Pre-Cardiac Transplant Amiodarone Use Increases Postoperative Mortality: A Meta-analysis
‡9
1
|
|
919
|
|
|
‡a
prasugrelacriticalcomparisonwithclopidogrel
‡A
Prasugrel: a critical comparison with clopidogrel.
‡9
1
|
|
919
|
|
|
‡a
postoperativeatrialfibrillationwhatdowereallyknow
‡A
Postoperative atrial fibrillation - what do we really know?
‡9
1
|
|
919
|
|
|
‡a
postcardiothoracicsurgeryatrialfibrillationareviewofpreventivestrategies
‡A
Post-cardiothoracic surgery atrial fibrillation: a review of preventive strategies.
‡9
1
|
|
919
|
|
|
‡a
pitavastatinanew3hydroxy3methylglutarylcoenzymeareductaseinhibitorforthetreatmentofhyperlipidemia
‡A
Pitavastatin: a new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia.
‡9
1
|
|
919
|
|
|
‡a
pharmacologictreatmentofadvancedparkinsonsdiseaseametaanalysisofcomtinhibitorsandmaobinhibitors
‡A
Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors
‡9
1
|
|
919
|
|
|
‡a
pharmacogeneticsandoralantithromboticdrugs
‡A
Pharmacogenetics and oral antithrombotic drugs
‡9
1
|
|
919
|
|
|
‡a
outcomesassociatedwithmammaliantargetofrapamycinmtorinhibitorsinhearttransplantrecipientsametaanalysis
‡A
Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: A meta-analysis.
‡9
1
|
|
919
|
|
|
‡a
outcomesassociatedwithmammaliantargetofrapamycin
‡A
Outcomes associated with mammalian target of rapamycin
‡9
1
|
|
919
|
|
|
‡a
oralantidiabeticdrugsandregressionfromprediabetestonormoglycemiaametaanalysis
‡A
Oral antidiabetic drugs and regression from prediabetes to normoglycemia: a meta-analysis
‡9
1
|
|
919
|
|
|
‡a
novelanticoagulantsforstrokepreventioninatrialfibrillationasystematicreviewofcosteffectivenessmodels
‡A
Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models.
‡9
1
|
|
919
|
|
|
‡a
neworalanticoagulantsvswarfarintreatmentnoneedforpharmacogenomics
‡A
New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics?
‡9
1
|
|
919
|
|
|
‡a
mythbustersdietarysupplementsandcovid19
‡A
Myth Busters: Dietary Supplements and COVID-19
‡9
1
|
|
919
|
|
|
‡a
methodsusedtoconductandreportbayesianmixedtreatmentcomparisonspublishedinthemedicalliteratureasystematicreview
‡A
Methods used to conduct and report Bayesian mixed treatment comparisons published in the medical literature: a systematic review
‡9
1
|
|
919
|
|
|
‡a
metaanalysisoftimeintherapeuticrangeincontinuousflowleftventricularassistdevicepatientsreceivingwarfarin
‡A
Meta-Analysis of Time in Therapeutic Range in Continuous-Flow Left Ventricular Assist Device Patients Receiving Warfarin.
‡9
1
|
|
919
|
|
|
‡a
metaanalysisofoptimalriskstratificationinpatients65yearsofage
‡A
Meta-analysis of optimal risk stratification in patients >65 years of age
‡9
1
|
|
919
|
|
|
‡a
medicationsforasthma
‡A
Medications for Asthma
‡9
1
|
|
919
|
|
|
‡a
medicationadherenceandnonvitaminkantagonistoralanticoagulantswhatdowereallyknow
‡A
Medication adherence and non-vitamin K antagonist oral anticoagulants: what do we really know?
‡9
1
|
|
919
|
|
|
‡a
mechanicalendovasculartherapyforacuteischemicstrokeanindirecttreatmentcomparisonbetweensolitaireandpenumbrathrombectomydevices
‡A
Mechanical endovascular therapy for acute ischemic stroke: An indirect treatment comparison between Solitaire and Penumbra thrombectomy devices.
‡9
1
|
|
919
|
|
|
‡a
mammaliantargetofrapamycininhibitorsandsurvivalinhearttransplantrecipientsmiracleormirage
‡A
Mammalian Target of Rapamycin Inhibitors and Survival in Heart Transplant Recipients: Miracle or Mirage?
‡9
1
|
|
919
|
|
|
‡a
lorcaserinanovelserotonin2cagonistforthetreatmentofobesity
‡A
Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity
‡9
1
|
|
919
|
|
|
‡a
letterbybakeretalregardingarticlebenefitsandrisksofcorticosteroidprophylaxisinadultcardiacsurgeryadoseresponsemetaanalysis
‡A
Letter by Baker et al regarding article, "benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response meta-analysis"
‡9
1
|
|
919
|
|
|
‡a
keyarticlesandguidelinesintheprimarypreventionofischemicstroke
‡A
Key articles and guidelines in the primary prevention of ischemic stroke.
‡9
1
|
|
919
|
|
|
‡a
keyarticlesandguidelinesinthemanagementofpatientsundergoingcardiacsurgery
‡A
Key articles and guidelines in the management of patients undergoing cardiac surgery
‡9
1
|
|
919
|
|
|
‡a
keyarticlesandguidelinesintheacutemanagementandsecondarypreventionofischemicstroke
‡A
Key articles and guidelines in the acute management and secondary prevention of ischemic stroke
‡9
1
|
|
919
|
|
|
‡a
intravenousacetaminophenforpostoperativepainmanagementinpatientsundergoinglivinglaparoscopiclivingdonornephrectomy
‡A
Intravenous Acetaminophen for Postoperative Pain Management in Patients Undergoing Living Laparoscopic Living-Donor Nephrectomy
‡9
1
|
|
919
|
|
|
‡a
intermittentinhaledcorticosteroidsandlongactingmuscarinicantagonistsforasthma
‡A
Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma
‡9
1
|
|
919
|
|
|
‡a
intensiveversusstandardbloodpressurecontrolinsprinteligibleparticipantsofaccordbp
‡A
Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP.
‡9
1
|
|
919
|
|
|
‡a
influenceofpolypharmacyontheeffectivenessandsafetyofrivaroxabanversuswarfarininpatientswithnonvalvularatrialfibrillation
‡A
Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation
‡9
1
|
|
919
|
|
|
‡a
increasedclinicalfailureswhentreatingacuteotitismediawithmacrolidesametaanalysis
‡A
Increased clinical failures when treating acute otitis media with macrolides: a meta-analysis
‡9
1
|
|
919
|
|
|
‡a
improvingpeerreviewwhatreviewerscando
‡A
Improving peer review: What reviewers can do.
‡9
1
|
|
919
|
|
|
‡a
improvingpeerreviewwhatjournalscando
‡A
Improving peer review: What journals can do.
‡9
1
|
|
919
|
|
|
‡a
improvingpeerreviewwhatauthorscando
‡A
Improving peer review: What authors can do.
‡9
1
|
|
919
|
|
|
‡a
improvedglucosecontrolassociatedwith15chromiumadministrationin2patientsreceivingenteralnutrition
‡A
Improved glucose control associated with i.v. chromium administration in two patients receiving enteral nutrition
‡9
1
|
|
919
|
|
|
‡a
impactofprolongedanticoagulationwithrivaroxabanonprovokedvenousthromboembolismrecurrenceimprovevte
‡A
Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE
‡9
1
|
|
919
|
|
|
‡a
hemodynamicandelectrocardiographiceffectsofacaiberryinhealthyvolunteersarandomizedcontrolledtrial
‡A
Hemodynamic and electrocardiographic effects of açaí berry in healthy volunteers: a randomized controlled trial
‡9
1
|
|
919
|
|
|
‡a
haematologicalindicesaspredictorsofatrialfibrillationfollowingisolatedcoronaryarterybypassgraftingvalvularsurgeryorcombinedproceduresasystematicreviewwithmetaanalysis
‡A
Haematological indices as predictors of atrial fibrillation following isolated coronary artery bypass grafting, valvular surgery, or combined procedures: a systematic review with meta-analysis
‡9
1
|
|
919
|
|
|
‡a
4yearincidenceofmajoradversecardiovasculareventsinpatientswithatherosclerosisandatrialfibrillation
‡A
Four-year incidence of major adverse cardiovascular events in patients with atherosclerosis and atrial fibrillation
‡9
1
|
|
919
|
|
|
‡a
evaluationofposttransplantationdiabetesmellitusafterlivertransplantationassessmentofinsulinadministrationasariskfactor
‡A
Evaluation of Posttransplantation Diabetes Mellitus After Liver Transplantation: Assessment of Insulin Administration as a Risk Factor.
‡9
1
|
|
919
|
|
|
‡a
evaluatingtheimpactofstudylevelfactorsonwarfarincontrolinusbasedprimarystudiesametaanalysis
‡A
Evaluating the impact of study-level factors on warfarin control in U.S.-based primary studies: a meta-analysis.
‡9
1
|
|
919
|
|
|
‡a
evaluatingcardiovascularsafetyofnoveltherapeuticagentsforthetreatmentoftype2diabetesmellitus
‡A
Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus
‡9
1
|
|
919
|
|
|
‡a
erratumintensiveversusstandardbloodpressurecontrolinsprinteligibleparticipantsofaccordbpdiabetescare2017401733
‡A
Erratum. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. Diabetes Care 2017;40:1733-1738
‡9
1
|
|
919
|
|
|
‡a
electrocardiographiceffectsofhawthorncrataegusoxyacanthainhealthyvolunteersarandomizedcontrolledtrial
‡A
Electrocardiographic effects of hawthorn (Crataegus oxyacantha) in healthy volunteers: A randomized controlled trial
‡9
1
|
|
919
|
|
|
‡a
efficacyofazilsartanmedoxomilwithchlorthalidoneinhypertension
‡A
Efficacy of azilsartan medoxomil with chlorthalidone in hypertension
‡9
1
|
|
919
|
|
|
‡a
effectsofsodiumglucosecotransporter2inhibitorson24hourambulatorybloodpressureasystematicreviewandmetaanalysis
‡A
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis
‡9
1
|
|
919
|
|
|
‡a
effectsofsodiumglucosecotransporter2inhibitorsonbloodpressureasystematicreviewandmetaanalysis
‡A
Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis
‡9
1
|
|
919
|
|
|
‡a
effectivenessandsafetyofrivaroxabaninpatientswithcancerassociatedvenousthrombosis
‡A
Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis
‡9
1
|
|
919
|
|
|
‡a
effectofperioperativecorticosteroiduseontheincidenceofpostcardiothoracicsurgeryatrialfibrillationandlengthofstay
‡A
Effect of perioperative corticosteroid use on the incidence of postcardiothoracic surgery atrial fibrillation and length of stay.
‡9
1
|
|
919
|
|
|
‡a
effectofnonergotdopamineagonistsonsymptomsofrestlesslegssyndrome
‡A
Effect of nonergot dopamine agonists on symptoms of restless legs syndrome.
‡9
1
|
|
919
|
|
|
‡a
effectofmagnesium50lactateonbloodpressureinpatientswithanimplantablecardioverterdefibrillator
‡A
Effect of magnesium L-lactate on blood pressure in patients with an implantable cardioverter defibrillator
‡9
1
|
|
919
|
|
|
‡a
effectofintensivebloodpressurecontrolinpatientswithtype2diabetesmellitusover9yearsoffollowupasubgroupanalysisofhighriskaccordiontrialparticipants
‡A
Effect of Intensive Blood Pressure Control in Patients with Type 2 Diabetes Mellitus Over 9 Years of Follow-Up: A Subgroup Analysis of High-Risk ACCORDION Trial Participants.
‡9
1
|
|
919
|
|
|
‡a
effectofdehydroepiandrosteroneonmusclestrengthandphysicalfunctioninolderadultsasystematicreview
‡A
Effect of dehydroepiandrosterone on muscle strength and physical function in older adults: a systematic review.
‡9
1
|
|
919
|
|
|
‡a
effectofcinnamononglucosecontrolandlipidparameters
‡A
Effect of cinnamon on glucose control and lipid parameters
‡9
1
|
|
919
|
|
|
‡a
effectofascorbicacidoninflammatorymarkersaftercardiothoracicsurgery
‡A
Effect of ascorbic acid on inflammatory markers after cardiothoracic surgery
‡9
1
|
|
919
|
|
|
‡a
associationbetweenchads2riskfactorsandanticoagulationrelatedbleedingasystematicliteraturereview
‡A
Association between CHADS₂risk factors and anticoagulation-related bleeding: a systematic literature review.
‡9
1
|
|
919
|
|
|
‡a
associationbetweenhbsagpositivityandpancreaticcancerametaanalysis
‡A
Association between HBsAg positivity and pancreatic cancer: a meta-analysis
‡9
1
|
|
919
|
|
|
‡a
associationbetweenperioperativensaiduseandpostcardiothoracicsurgeryatrialfibrillationbloodtransfusionsandcardiovascularoutcomesanestedcohortstudyfromtheafsuppressiontrialsafist12and3
‡A
Association between perioperative NSAID use and post-cardiothoracic surgery atrial fibrillation, blood transfusions, and cardiovascular outcomes: a nested cohort study from the AF Suppression Trials (AFIST) I, II and III
‡9
1
|
|
919
|
|
|
‡a
associationbetweentimeintherapeutictacrolimusrangeandearlyrejectionafterhearttransplant
‡A
Association Between Time-in-Therapeutic Tacrolimus Range and Early Rejection After Heart Transplant
‡9
1
|
|
919
|
|
|
‡a
associationbetweenweekendadmissionandmortalityforuppergastrointestinalhemorrhageanobservationalstudyandmetaanalysis
‡A
Association between weekend admission and mortality for upper gastrointestinal hemorrhage: an observational study and meta-analysis.
‡9
1
|
|
919
|
|
|
‡a
associationofinhaledcorticosteroidsandlongactingmuscarinicantagonistswithasthmacontrolinpatientswithuncontrolledpersistentasthmaasystematicreviewandmetaanalysis
‡A
Association of Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists With Asthma Control in Patients With Uncontrolled, Persistent Asthma: A Systematic Review and Meta-analysis
‡9
1
|
|
919
|
|
|
‡a
associationofinhaledcorticosteroidsandlongactingβagonistsascontrollerandquickrelieftherapywithexacerbationsandsymptomcontrolinpersistentasthmaasystematicreviewandmetaanalysis
‡A
Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis
‡9
1
|
|
919
|
|
|
‡a
dopamineagonistsinthetreatmentofearlyparkinsonsdiseaseametaanalysis
‡A
Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis
‡9
1
|
|
919
|
|
|
‡a
developmentofcriticalthinkinginhealthprofessionseducationametaanalysisoflongitudinalstudies
‡A
Development of critical thinking in health professions education: A meta-analysis of longitudinal studies
‡9
1
|
|
919
|
|
|
‡a
deathsandcardiovasculareventsinmenreceivingtestosterone
‡A
Deaths and cardiovascular events in men receiving testosterone
‡9
1
|
|
919
|
|
|
‡a
dabigatrananoraldirectthrombininhibitorforuseinatrialfibrillation
‡A
Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation
‡9
1
|
|
919
|
|
|
‡a
currentstatusofpatientradiationexposureofcardiacpositronemissiontomographyandsinglephotonemissioncomputedtomographicmyocardialperfusionimaging
‡A
Current Status of Patient Radiation Exposure of Cardiac Positron Emission Tomography and Single-Photon Emission Computed Tomographic Myocardial Perfusion Imaging
‡9
1
|
|
919
|
|
|
‡a
cryoballoonablationforthetreatmentofatrialfibrillationametaanalysis
‡A
Cryoballoon Ablation for the Treatment of Atrial Fibrillation: A Meta-analysis
‡9
1
|
|
919
|
|
|
‡a
comparativeeffectivenessofanalgesicstoreduceacutepainintheprehospitalsetting
‡A
Comparative Effectiveness of Analgesics to Reduce Acute Pain in the Prehospital Setting
‡9
1
|
|
919
|
|
|
‡a
commonflawsexistinpublishedcosteffectivenessmodelsofpharmacologicstrokepreventioninatrialfibrillation
‡A
Common flaws exist in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillation
‡9
1
|
|
919
|
|
|
‡a
combinationtherapyforthemanagementofhypertensionareviewoftheevidence
‡A
Combination therapy for the management of hypertension: A review of the evidence.
‡9
1
|
|
919
|
|
|
‡a
cinnamonuseintype2diabetesanupdatedsystematicreviewandmetaanalysis
‡A
Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis
‡9
1
|
|
919
|
|
|
‡a
cardiovasculareffectsofpharmacologictherapiesforsmokingcessation
‡A
Cardiovascular effects of pharmacologic therapies for smoking cessation
‡9
1
|
|
919
|
|
|
‡a
cardiovasculareffectsofincretinbasedtherapies
‡A
Cardiovascular Effects of Incretin-Based Therapies
‡9
1
|
|
919
|
|
|
‡a
cardiacmriconfirmedmesalamineinducedmyocarditis
‡A
Cardiac MRI-confirmed mesalamine-induced myocarditis
‡9
1
|
|
919
|
|
|
‡a
canagliflozinanovelsglt2inhibitorfortreatmentoftype2diabetes
‡A
Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes
‡9
1
|
|
919
|
|
|
‡a
canapixabanpreventvenousthromboembolismbetterthanrivaroxaban
‡A
Can apixaban prevent venous thromboembolism better than rivaroxaban?
‡9
1
|
|
919
|
|
|
‡a
beyondtheguidelinesnewandnovelagentsforthepreventionofatrialfibrillationaftercardiothoracicsurgery
‡A
Beyond the guidelines: new and novel agents for the prevention of atrial fibrillation after cardiothoracic surgery
‡9
1
|
|
919
|
|
|
‡a
benefitsandrisksassociatedwithbetablockerprophylaxisinnoncardiacsurgery
‡A
Benefits and risks associated with beta-blocker prophylaxis in noncardiac surgery.
‡9
1
|
|
919
|
|
|
‡a
benefitriskassessmentofpitavastatinforthetreatmentofhypercholesterolemiainolderpatients
‡A
Benefit-risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients
‡9
1
|
|
919
|
|
|
‡a
bdnfval66metpolymorphismandlithiumresponseametaanalysis
‡A
BDNF Val66Met polymorphism and lithium response: a meta-analysis
‡9
1
|
|
943
|
|
|
‡a
173x
‡A
1738
‡9
2
|
|
946
|
|
|
‡a
b
‡9
1
|
|
996
|
|
|
‡2
BIBSYS|98039610
|
|
996
|
|
|
‡2
JPG|500103490
|
|
996
|
|
|
‡2
DNB|1256044180
|
|
996
|
|
|
‡2
SUDOC|232579229
|
|
996
|
|
|
‡2
NSK|000057584
|
|
996
|
|
|
‡2
NUKAT|n 2003095863
|
|
996
|
|
|
‡2
LC|no2001035697
|
|
996
|
|
|
‡2
LC|no2004066416
|
|
996
|
|
|
‡2
ISNI|0000000054174189
|
|
996
|
|
|
‡2
LC|n 2011023588
|
|
996
|
|
|
‡2
NTA|072265116
|
|
996
|
|
|
‡2
LC|no2024108462
|
|
996
|
|
|
‡2
ISNI|000000007958263X
|
|
996
|
|
|
‡2
CAOONL|ncf10793482
|
|
996
|
|
|
‡2
LC|nr 96017451
|
|
996
|
|
|
‡2
J9U|987007463213405171
|
|
996
|
|
|
‡2
LC|no2010171533
|
|
996
|
|
|
‡2
LC|n 2007036444
|
|
996
|
|
|
‡2
LC|no2023108749
|
|
996
|
|
|
‡2
LC|n 83155189
|
|
996
|
|
|
‡2
ISNI|0000000119130495
|
|
996
|
|
|
‡2
LC|no 91012628
|
|
996
|
|
|
‡2
NUKAT|n 2012042881
|
|
996
|
|
|
‡2
ISNI|0000000006513975
|
|
996
|
|
|
‡2
DNB|1158468237
|
|
996
|
|
|
‡2
ISNI|0000000107860503
|
|
996
|
|
|
‡2
JPG|500257678
|
|
996
|
|
|
‡2
NII|DA10086807
|
|
996
|
|
|
‡2
LC|no 94043658
|
|
996
|
|
|
‡2
BIBSYS|11051502
|
|
996
|
|
|
‡2
BIBSYS|90361245
|
|
996
|
|
|
‡2
JPG|500111273
|
|
996
|
|
|
‡2
SUDOC|145496422
|
|
996
|
|
|
‡2
LC|n 83148407
|
|
996
|
|
|
‡2
CAOONL|ncf10078615
|
|
996
|
|
|
‡2
NUKAT|n 2014195049
|
|
996
|
|
|
‡2
LC|no2008184439
|
|
996
|
|
|
‡2
BNF|12461342
|
|
996
|
|
|
‡2
PLWABN|9810704068605606
|
|
996
|
|
|
‡2
LC|n 93099339
|
|
996
|
|
|
‡2
J9U|987007453831005171
|
|
996
|
|
|
‡2
ISNI|000000005475532X
|
|
996
|
|
|
‡2
JPG|500144977
|
|
996
|
|
|
‡2
LC|n 94098783
|
|
996
|
|
|
‡2
LC|n 98097410
|
|
996
|
|
|
‡2
LC|n 85184278
|
|
996
|
|
|
‡2
ISNI|000000008433573X
|
|
996
|
|
|
‡2
ISNI|0000000033593843
|
|
996
|
|
|
‡2
ISNI|0000000445033674
|
|
996
|
|
|
‡2
J9U|987007350730705171
|
|
996
|
|
|
‡2
ISNI|000000004341356X
|
|
996
|
|
|
‡2
LC|n 87100514
|
|
996
|
|
|
‡2
LC|n 50015976
|
|
996
|
|
|
‡2
ISNI|0000000020984140
|
|
996
|
|
|
‡2
ISNI|0000000024149265
|
|
996
|
|
|
‡2
LC|no2022028280
|
|
996
|
|
|
‡2
LC|n 97083004
|
|
996
|
|
|
‡2
ISNI|0000000058514857
|
|
996
|
|
|
‡2
LC|no2001068587
|
|
996
|
|
|
‡2
LC|n 87137546
|
|
996
|
|
|
‡2
BIBSYS|63888
|
|
996
|
|
|
‡2
LC|no2011074635
|
|
996
|
|
|
‡2
ISNI|0000000067076844
|
|
996
|
|
|
‡2
SUDOC|275538311
|
|
996
|
|
|
‡2
NKC|utb2015878219
|
|
996
|
|
|
‡2
ISNI|0000000360698175
|
|
996
|
|
|
‡2
CAOONL|ncf11318631
|
|
996
|
|
|
‡2
N6I|vtls000060771
|
|
996
|
|
|
‡2
DNB|1073540537
|
|
996
|
|
|
‡2
NUKAT|n 2011140618
|
|
996
|
|
|
‡2
SUDOC|273810634
|
|
996
|
|
|
‡2
LC|no2005025773
|
|
996
|
|
|
‡2
DNB|118908715
|
|
996
|
|
|
‡2
ISNI|0000000051834671
|
|
996
|
|
|
‡2
J9U|987007274627705171
|
|
996
|
|
|
‡2
NLA|000035012513
|
|
996
|
|
|
‡2
N6I|vtls001092157
|
|
996
|
|
|
‡2
ISNI|0000000074344982
|
|
996
|
|
|
‡2
LC|n 2012057460
|
|
996
|
|
|
‡2
DNB|1024866505
|
|
996
|
|
|
‡2
J9U|987012330095105171
|
|
996
|
|
|
‡2
J9U|987007318715705171
|
|
996
|
|
|
‡2
NUKAT|n 2013230529
|
|
996
|
|
|
‡2
ISNI|0000000115196067
|
|
996
|
|
|
‡2
ISNI|0000000077529093
|
|
996
|
|
|
‡2
J9U|987007302368405171
|
|
996
|
|
|
‡2
NYNYRILM|293829
|
|
996
|
|
|
‡2
BNC|981058520702006706
|
|
996
|
|
|
‡2
LC|n 2015186448
|
|
996
|
|
|
‡2
N6I|vtls001350118
|
|
996
|
|
|
‡2
ISNI|0000000366341150
|
|
996
|
|
|
‡2
RERO|A012492200
|
|
996
|
|
|
‡2
DNB|1081913401
|
|
996
|
|
|
‡2
LC|no2020058064
|
|
996
|
|
|
‡2
BIBSYS|90114221
|
|
996
|
|
|
‡2
NKC|xx0198538
|
|
996
|
|
|
‡2
LC|n 2011181866
|
|
996
|
|
|
‡2
LC|nb2016013965
|
|
996
|
|
|
‡2
NTA|134500814
|
|
996
|
|
|
‡2
ISNI|0000000027494435
|
|
996
|
|
|
‡2
NTA|069662967
|
|
996
|
|
|
‡2
LC|nb2022014076
|
|
996
|
|
|
‡2
LC|n 2014189932
|
|
996
|
|
|
‡2
NII|DA16584294
|
|
996
|
|
|
‡2
LC|n 2006166459
|
|
996
|
|
|
‡2
LC|n 87870360
|
|
996
|
|
|
‡2
LC|n 95112383
|
|
996
|
|
|
‡2
LC|no2003106921
|
|
996
|
|
|
‡2
SUDOC|059448261
|
|
996
|
|
|
‡2
DNB|124866727
|
|
996
|
|
|
‡2
DNB|1055930477
|
|
996
|
|
|
‡2
ISNI|0000000028275840
|
|
996
|
|
|
‡2
BNF|16541030
|
|
996
|
|
|
‡2
SUDOC|236301578
|
|
996
|
|
|
‡2
DBC|87097969374123
|
|
996
|
|
|
‡2
RERO|A022779321
|
|
996
|
|
|
‡2
DBC|87097969373968
|
|
996
|
|
|
‡2
NTA|091185254
|
|
996
|
|
|
‡2
RERO|A002962168
|
|
996
|
|
|
‡2
ISNI|0000000027412401
|
|
996
|
|
|
‡2
SUDOC|143244264
|
|
996
|
|
|
‡2
N6I|vtls001260225
|
|
996
|
|
|
‡2
LC|no2012079758
|
|
996
|
|
|
‡2
BNF|14464260
|
|
996
|
|
|
‡2
NTA|315066016
|
|
996
|
|
|
‡2
ISNI|0000000025621891
|
|
996
|
|
|
‡2
ISNI|0000000032202564
|
|
996
|
|
|
‡2
BNF|13776026
|
|
996
|
|
|
‡2
DNB|119154463
|
|
996
|
|
|
‡2
ISNI|0000000081554814
|
|
996
|
|
|
‡2
LNB|LNC10-000072948
|
|
996
|
|
|
‡2
JPG|500011886
|
|
996
|
|
|
‡2
BNF|12072985
|
|
996
|
|
|
‡2
LC|n 81131390
|
|
996
|
|
|
‡2
J9U|987007422415905171
|
|
996
|
|
|
‡2
BIBSYS|8062870
|
|
996
|
|
|
‡2
DNB|123620641X
|
|
996
|
|
|
‡2
LC|n 2022003498
|
|
996
|
|
|
‡2
ISNI|0000000064013186
|
|
996
|
|
|
‡2
SUDOC|273448110
|
|
996
|
|
|
‡2
NLA|000035808783
|
|
996
|
|
|
‡2
JPG|500036786
|
|
996
|
|
|
‡2
JPG|500036785
|
|
996
|
|
|
‡2
SUDOC|150849699
|
|
996
|
|
|
‡2
LC|n 88146883
|
|
996
|
|
|
‡2
ISNI|0000000023025287
|
|
996
|
|
|
‡2
ISNI|0000000050416830
|
|
996
|
|
|
‡2
ISNI|0000000047471142
|
|
996
|
|
|
‡2
SUDOC|134481550
|
|
996
|
|
|
‡2
SUDOC|266939031
|
|
996
|
|
|
‡2
SELIBR|326996
|
|
996
|
|
|
‡2
SUDOC|033785821
|
|
996
|
|
|
‡2
LIH|LNB:B_h__t_0;=B_u_
|
|
996
|
|
|
‡2
DNB|1050420225
|
|
996
|
|
|
‡2
BAV|495_95733
|
|
996
|
|
|
‡2
LC|ns2024003295
|
|
996
|
|
|
‡2
NYNYRILM|208354
|
|
996
|
|
|
‡2
NKC|ola2003204839
|
|
996
|
|
|
‡2
SUDOC|059778121
|
|
996
|
|
|
‡2
CAOONL|ncf12092281
|
|
996
|
|
|
‡2
LC|n 2011041737
|
|
996
|
|
|
‡2
DNB|1216430772
|
|
996
|
|
|
‡2
LC|nb2014008533
|
|
996
|
|
|
‡2
LC|n 2015033357
|
|
996
|
|
|
‡2
LC|n 91067772
|
|
996
|
|
|
‡2
LC|nr 90022346
|
|
996
|
|
|
‡2
SUDOC|168474808
|
|
996
|
|
|
‡2
LC|n 81105788
|
|
996
|
|
|
‡2
BIBSYS|90052669
|
|
996
|
|
|
‡2
J9U|987007432106205171
|
|
996
|
|
|
‡2
ISNI|0000000051044741
|
|
996
|
|
|
‡2
LC|n 2017180558
|
|
996
|
|
|
‡2
ISNI|0000000037458307
|
|
996
|
|
|
‡2
LC|n 2001028911
|
|
996
|
|
|
‡2
BIBSYS|90707953
|
|
996
|
|
|
‡2
SUDOC|248359193
|
|
996
|
|
|
‡2
N6I|vtls000080808
|
|
996
|
|
|
‡2
NKC|jn20021017002
|
|
996
|
|
|
‡2
LC|nb2014001544
|
|
996
|
|
|
‡2
LC|nb2008006210
|
|
996
|
|
|
‡2
LC|no2017063121
|
|
996
|
|
|
‡2
LC|nr 93046936
|
|
996
|
|
|
‡2
J9U|987007353032305171
|
|
996
|
|
|
‡2
LC|no2007058785
|
|
996
|
|
|
‡2
LC|no2009169241
|
|
996
|
|
|
‡2
CAOONL|ncf10207806
|
|
996
|
|
|
‡2
ISNI|0000000497672179
|
|
996
|
|
|
‡2
NYNYRILM|21810
|
|
996
|
|
|
‡2
LC|n 83065550
|
|
996
|
|
|
‡2
SUDOC|156107120
|
|
996
|
|
|
‡2
ISNI|0000000091295545
|
|
996
|
|
|
‡2
LC|n 83235817
|
|
996
|
|
|
‡2
ISNI|0000000454421986
|
|
996
|
|
|
‡2
PLWABN|9810648728905606
|
|
996
|
|
|
‡2
LC|n 81030695
|
|
996
|
|
|
‡2
BIBSYS|90952237
|
|
996
|
|
|
‡2
LC|no 98097244
|
|
996
|
|
|
‡2
LC|n 95802742
|
|
996
|
|
|
‡2
NTA|108710041
|
|
996
|
|
|
‡2
ISNI|0000000392373594
|
|
996
|
|
|
‡2
ISNI|0000000409169662
|
|
996
|
|
|
‡2
NKC|osd2018994211
|
|
996
|
|
|
‡2
LC|n 87133259
|
|
996
|
|
|
‡2
ISNI|0000000081657610
|
|
996
|
|
|
‡2
PLWABN|9813255110605606
|
|
996
|
|
|
‡2
SUDOC|087587475
|
|
996
|
|
|
‡2
LC|no 93035628
|
|
996
|
|
|
‡2
SUDOC|110547403
|
|
996
|
|
|
‡2
CAOONL|ncf10084385
|
|
996
|
|
|
‡2
NTA|069406944
|
|
996
|
|
|
‡2
NTA|071598081
|
|
996
|
|
|
‡2
LC|no2005009992
|
|
996
|
|
|
‡2
LC|no 98025994
|
|
996
|
|
|
‡2
ISNI|0000000045381725
|
|
996
|
|
|
‡2
NTA|074288377
|
|
996
|
|
|
‡2
ISNI|000000002621629X
|
|
996
|
|
|
‡2
LC|n 84202569
|
|
996
|
|
|
‡2
SUDOC|185800556
|
|
996
|
|
|
‡2
ISNI|0000000031241377
|
|
996
|
|
|
‡2
ISNI|0000000401650697
|
|
996
|
|
|
‡2
RERO|A022802171
|
|
996
|
|
|
‡2
NUKAT|n 97007006
|
|
996
|
|
|
‡2
LC|nr 92020772
|
|
996
|
|
|
‡2
NUKAT|n 2019007492
|
|
996
|
|
|
‡2
ISNI|0000000116181035
|
|
996
|
|
|
‡2
SUDOC|09227661X
|
|
996
|
|
|
‡2
SUDOC|13596699X
|
|
996
|
|
|
‡2
LC|n 80020251
|
|
996
|
|
|
‡2
DNB|132600854
|
|
996
|
|
|
‡2
LC|no2015009159
|
|
996
|
|
|
‡2
BIBSYS|1065635
|
|
996
|
|
|
‡2
LC|no2008115576
|
|
996
|
|
|
‡2
LC|n 2003091004
|
|
996
|
|
|
‡2
CAOONL|ncf10018749
|
|
996
|
|
|
‡2
ISNI|0000000045934377
|
|
996
|
|
|
‡2
J9U|987007258127505171
|
|
996
|
|
|
‡2
LC|nb2021002642
|
|
996
|
|
|
‡2
NTA|320507262
|
|
996
|
|
|
‡2
ISNI|0000000026211536
|
|
996
|
|
|
‡2
LC|no2003054943
|
|
996
|
|
|
‡2
NUKAT|n 2008103551
|
|
996
|
|
|
‡2
BNF|16184067
|
|
996
|
|
|
‡2
ISNI|0000000109300411
|
|
996
|
|
|
‡2
ISNI|0000000046808516
|
|
996
|
|
|
‡2
NII|DA01015455
|
|
996
|
|
|
‡2
NUKAT|n 2007103771
|
|
996
|
|
|
‡2
LC|no2008063543
|
|
996
|
|
|
‡2
NTA|070945748
|
|
996
|
|
|
‡2
J9U|987007319873105171
|
|
996
|
|
|
‡2
ISNI|0000000039629886
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
|
998
|
|
|
‡a
Baker, William L.
‡2
PLWABN|9810698560505606
‡3
viafid
‡3
exact title: (1.00, 'haematologicalindicesaspredictorsofatrialfibrillationfollowingisolatedcoronaryarterybypassgraftingvalvularsurgeryorcombinedproceduresasystematicreviewwithmetaanalysis', 'haematologicalindicesaspredictorsofatrialfibrillationfollowingisolatedcoronaryarterybypassgraftingvalvularsurgeryorcombinedproceduresasystematicreviewwithmetaanalysis')
|
